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Abstract
Age-related macular degeneration (AMD) is the leading cause of central vision loss worldwide. Loss of retinal
pigment epithelium (RPE) is a major pathological hallmark in AMD with or without pathological neovascularization.
Although activation of the immune system is implicated in disease progression, pathological pathways remain
diverse and unclear. Here, we report an unexpected protective role of a pro-inflammatory cytokine, interleukin-33
(IL-33), in ocular angiogenesis. IL-33 and its receptor (ST2) are expressed constitutively in human and murine
retina and choroid. When RPE was activated, IL-33 expression was markedly elevated in vitro. We found that
IL-33 regulated tissue remodelling by attenuating wound-healing responses, including reduction in the migration
of choroidal fibroblasts and retinal microvascular endothelial cells, and inhibition of collagen gel contraction. In
vivo, local administration of recombinant IL-33 inhibited murine choroidal neovascularization (CNV) formation,
a surrogate of human neovascular AMD, and this effect was ST2-dependent. Collectively, these data demonstrate
IL-33 as a potential immunotherapy and distinguishes pathways for subverting AMD pathology.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Age-related macular degeneration (AMD) is the lead-
ing cause of visual loss in developed countries, affect-
ing one in ten people older than 50 years (http://www
.amdalliance.org). With a global increase in the age-
ing population, the numbers suffering with this progres-
sive disease are expected to increase in 2050 by 50%
[1]. AMD is a progressive, polygenic, and multifacto-
rial disease leading to a clinico-pathological spectrum of
cell loss and atrophy and neovascularization. Although
current anti-vascular endothelial growth factor (VEGF)
therapies have revolutionized treatment for neovascu-
lar (n)AMD, we are treating late in disease, only after
the insidious progression of degeneration has ensued.
Tailoring therapies to treat early is desirable to over-
come the potential amplification of degenerative path-
ways, including neovascularization, and to offer, in such
cases, alternatives for those unresponsive to anti-VEGF
agents [2].
Altered immune responses are recognized as
integral to the pathogenesis of AMD [3]. The NLRP3
inflammasome has been reported to monitor cell stress
through pattern recognition receptors [e.g. Toll-like
receptors (TLRs)], activating inflammatory caspases
[4]. The activation of the NLRP3 inflammasome is
almost certainly a protective response initially, provid-
ing a rapid response to danger in order to preserve tissue
function and integrity. The corollary is that inflamma-
some activation may also cause tissue damage. So, why
patients convert from early or intermediate AMD (clini-
cally manifest as drusen and RPE changes) to advanced
AMD (including choroidal neovascularization) is pur-
ported to be as a switch from the ageing homeostatic
regulatory response [5] to a pathological inflammatory
response. For example, recent studies have shown
that the NLRP3 inflammasome, which is capable of
liberating active interleukin (IL) 1β and IL-18 produc-
tion, can ‘sense’ drusen isolated from human AMD
donor eyes. IL-18, however, has been shown to protect
against the development of choroidal neovascularization
(CNV) [6].
Given the controversy over the role of inflammasome
activation and the role for adjuvant immunotherapy in
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AMD treatment, we have investigated the role of the type
2 IL-1 family member IL-33 [7], which is unique as it is
active without caspase-1 cleavage and does not require
inflammasome activation for secretion and bioactivity
[8]. IL-33 is released following cellular damage [9] and
biomechanical overload [10], behaving as an ‘alarmin’
[11] that signals through the heterodimeric receptor con-
sisting of ST2 and IL-1R accessory protein [12]. The
membrane form of ST2 (IL1RL1) [13] is expressed on
many immune cells [14,15]. An alternative spliced sol-
uble form (sST2) acts as a decoy receptor of IL-33 [16].
In experimental autoimmune uveitis (EAU), IL-33 atten-
uates disease severity [17]. However, IL-33 triggers an
inflammatory response, recruitingmonocytes, contribut-
ing to photoreceptor loss in a photoxic retinal model of
degeneration [18], and this infers a pathogenic role for
endogenous IL-33 and offers an a priori rationale for
neutralizing IL-33 to reduce myeloid cell accumulation
as a possible intervention.
On the basis of the emerging role of IL-33 in inflam-
matory disorders [19,20] and the controversy over its
role, we hypothesized that IL-33/ST2 signalling in the
absence of overt cell death regulates tissue responses
in neovascular AMD disease pathology. We showed
that IL-33 subverts angiogenesis, via direct inhibition of
fibroblasts and endothelial cells that express high levels
of ST2. We further showed that recombinant IL-33 pro-
tects against CNV development. Our data provide new
insights into the regulation of angiogenesis by IL-33,
and are contrary to previous data.
Materials and methods
Cell culture
The murine B6-RPE07 and human ARPE-19 cell lines
were cultured in DMEM medium supplemented with
10% heat-inactivated fetal calf serum, 2% L-glutamine,
1 mM sodium pyruvate, 60 μM 2-mercaptoethanol, 100
U/ml penicillin, and 100 μg/ml streptomycin. Primary
human retinal and cerebral microvascular endothelial
cells (HRMECs and HCMECs) were purchased from
a commercial source (Innoprot, Derio-Bizkaia, Spain).
HRMECs were isolated from healthy retinal tissue and
were cryopreserved at passage 1 and delivered to our
laboratory frozen. The vendor had characterized cells
by immunofluorescent methods with antibodies directed
against VWF/Factor VIII and CD31 (P-CAM) and by
uptake of DiI-Ac-LDL. Human choroidal fibroblasts
were purchased from SciencCell Research Laboratories
(Carlsbad, CA, USA) and cultured in fibroblast medium
(SciencCell Research Laboratories).
Mice and in vivo experimental procedures
C57BL/6J mice were purchased from Charles River
Laboratories, Margate, UK. ST2 knock-out (St2−/−)
C57BL/6 mice (backcrossed for ten generations) were
kindly provided by C Emanueli (School of Clinical
Sciences, Bristol Heart Institute, University of Bris-
tol) and were generated as described earlier [20]. IL-33
knock-out (Il-33−/−) mice were generated as described
earlier [21]. Il33−/−mice were backcrossed for six gen-
erations to C57/Bl6J mice to remove the rd8 mutation.
All micewere used at 8–10weeks of age andmaintained
in the animal house facilities of the University of Bris-
tol, according to Home Office Regulations. Treatment of
the animals conformed to the Association for Research
in Vision and Ophthalmology (ARVO) statement.
CNV was induced by laser photocoagulation in mice;
four laser spots (power 200 mW, duration 75 ms, spot
size 75 μm) were delivered to the posterior retina using
an OculightSlx Krypton Red Laser system (IRIS Med-
ical, Iridex, Mountain View, CA, USA). Local admin-
istration of IL-33 (doses in 2 μl of normal saline) or
vehicle control was performed by intravitreal injection
using a 33-gauge hypodermic needle. Optical coherence
tomography (OCT) was performed using the Micron IV
(Phoenix Research Laboratories, Pleasanton, CA, USA)
to evaluate lesion size and retinal thickness.
Tissue preparation and immunofluorescence
staining
To prepare RPE/choroid whole-mounts, enucleated eyes
were initially fixed in 2% PFA overnight. Eyes were
dissected, and RPE/choroidal tissues were blocked and
permeabilized in 5% BSA with 0.3% Triton X-100 in
PBS for 2 h. For evaluation of CNV formation, the neo-
vascular membrane was stained with biotin-conjugated
isolectin B4 (IB4; Sigma-Aldrich, St Louis, MO, USA;
L2140; 1:100), followed by incubation with Rhodamine
Red-X-labelled streptavidin (Jackson Immuno Research
Laboratories, West Grove, PA, USA; 016-290-084;
1:400). The CNV volume was measured using a series
of Z-stack images (from the surface to the deepest focal
plane) using Volocity® Image Analysis Software 6.0.
TMR Red-dUTP TUNEL (Roche Diagnostics, Burgess
Hill, UK) staining of DNA breaks was performed on 10
μm cryosections of enucleated eyes from treated mice,
according to the manufacturer’s protocol.
Histology and immunohistochemistry
Eyes from treated mice were enucleated at various
time points and cryosections prepared. For immunos-
taining, sections were fixed in acetone and blocked
in 5% donkey serum, 3% BSA, and 0.3% Triton
X-100 in PBS. Sections were incubated with the
following primary antibodies – anti-IL-33 Nessy-1
(ALX-804-840; Enzo Life Sciences, Ltd, Exeter, UK;
1:1000), ST2 (3363; ProSci Inc, Poway, CA, USA;
1:1000), Iba1 (L2140; Sigma, St Louis, MO, USA;
1:100), IL1RAP (ab8110; Abcam, Cambridge, MA,
USA; 1:1000), c-kit (105816; Biolegend, San Diego,
CA, USA; 1:200), vimentin (ab92547; Abcam; 1:100)
and tryptase (BS7353; bioWORLD, Dublin, OH, USA;
1:400) – overnight at 4∘C. Sections were incubated
with the appropriate secondary antibody (Life Tech-
nologies, Paisley, UK) donkey anti-rabbit conjugated to
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AlexaFluor-488 or AlexaFluor-594, or donkey anti-rat
AlexaFluor-594 (Life Technologies; dilution 1:400) or
goat anti-rabbit Cy2 (Abcam). DAPI (Vector Labora-
tories, Peterborough, UK) was used to show nuclei in
sections.
Human ocular samples
Healthy adult (age 18–65 years) human post-mortem
eyes from anonymous donors collected by Moorfields
Eye Bank for corneal transplantation were fixed in 10%
formalin and embedded in paraffin wax. This work
was ethically approved by the NHS Research Ethics
Committee (10/H0106/57-14ETR41).
Recombinant proteins
Recombinant mouse IL-33 (ALX-522-101-C010) and
human IL-33 (ALX-522-098-C010) were purchased
from Enzo Life Sciences Ltd (Exeter, UK). The trun-
cated form of human IL-33 was generated as described
previously [22] and was a kind gift from Professor Sea-
mus Martin (Trinity College Dublin).
Proliferation and functional assays
Cell numbers were assessed using an MTT assay, with
absorbance measured at 570 nm. For migration assays,
cells were seeded at 1× 104 cells per culture-insert and
incubated overnight. Inserts were removed before addi-
tion of fresh medium with treatment or vehicle. Phase
contrast images were taken at 0 h and 4 h post-treatment
using a wide-field microscope (DM16000; Leica, Wet-
zlar, Germany). The whole area of gaps was quantified
by ImageJ 1.46r (National Institutes of Health, USA).
For Boyden chamber assays, cells were cultured in EBM
medium with treatment or vehicle for 24 h before the
supernatant was transferred to the lower chamber of a
24-well format Transwell (Corning, UK) for 16 h incu-
bation. The membranes of the upper chamber were fixed
with 4% PFA for 20 min, followed by staining with
DAPI for cell counting using confocal microscopy.
Cytokine measurements
IL-6 levels were measured with an ELISA and fol-
lowing the manufacturer’s instructions (550799;
BD Biosciences, San Jose, CA, USA). For western
blots, cells lysates were separated by SDS-PAGE gel
electrophoresis, and proteins were transferred to a
nitrocellulose membrane. Following blocking in 5%
milk–TBS–Tween-20, the membrane was subjected
to analysis using the anti-IL-33 Nessy-1 antibody
(ALX-804-840; Enzo Life Sciences; 1:1000), the ST2
antibody (3363; ProSci; 1:1000), and β-actin antibody
(4970; Cell Signaling Technology, Beverley, MA, USA;
1:1000).
Proteins were detected with HRP-conjugated poly-
clonal anti-mouse IgG and visualized using a chemilu-
minescent method (GE Healthcare Life Sciences, Little
Chalfont, Buckinghamshire, UK). RNA was extracted
using an RNeasyMini Kit (Qiagen, Hamburg, Germany)
before cDNA synthesis using the ImProm-IITMReverse
Transcription System (Promega, Fitchburg, WI, USA).
cDNA was amplified using the Power SYBR® Green
PCR Master Mix Reagent on a StepOne™ Applied
Biosystems Real-Time PCR System. Relative expres-
sion was calculated using Actb and RNA18S as reference
transcripts for mouse and human tissues, respectively.
Statistical analysis
Statistical analysis was performed using an unpaired
two-tailed Student’s t-test or ANOVA as indicated for
comparison between groups. p< 0.05 was considered
significant.
Results
IL-33 expression is induced in human and murine
RPE cells
The retinal pigment epithelium (RPE) is central to reti-
nal homeostasis. We first investigated the expression of
IL-33 and ST2 in established human and murine RPE
cell lines [23,24]. Both human (ARPE-19) and mouse
(B6RPE-07) RPE cells were stimulated with Toll-like
receptor (TLR) agonists, including TLR3 and TLR4
agonists [poly(I:C) and LPS], to simulate activation of
the innate immune response and inflammasome [4]. Our
data show that murine and human RPE cells constitu-
tively expressed IL-33 and its cognate receptor ST2, at
both mRNA and protein levels (Figure 1A–C). TLR
activation of RPE cells increased expression of IL-33
and ST2L (IL1RL1) mRNA in a dose-dependent manner,
although the effect of poly(I:C) was not as profound as
LPS stimulation (Figure 1A,B). The effect of TLR ago-
nists on IL-33 and ST2 induction was confirmed at the
protein level by western blot (Figure 1C). These results
demonstrate that IL-33 expression is up-regulated in the
RPE cells following an inflammatory stimulus.
IL-33 and its receptor ST2 are expressed in murine
and human retina
To establish expression patterns of IL-33 and ST2
in vivo, we examined normal eye tissues from naïve
C57BL/6J mice. Immunostaining of adult murine retina
demonstrated that IL-33 was expressed by cells in
the inner nuclear layer (INL) and RPE, with expres-
sion localized to the nuclei of Müller glial cells and
retinal microvascular endothelial cells, respectively
(Figure 1D). In the developing mouse retina, there is a
gradual but marked increase of IL-33 expression from
postnatal day 4 to postnatal day 10; the ciliary body was
similarly enriched (see supplementary material, Figure
S1A–C).
Immunostaining of choroid fromWT animals demon-
strated ST2 expression in RPE (phalloidin-stained), as
well as choroidal mast cells (c-kit+) and choroidal
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 45–56
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
48 S Theodoropoulou et al
Figure 1. IL-33 is expressed in murine and human retinas, and is induced in RPE. Expression of IL-33 (A) and its receptor, ST2L (B),
mRNA expression in retinal pigment epithelium (RPE) treated with TLR agonists [LPS, poly(I:C)] as indicated for 24 h (n= 4 per group).
(C) Western blot analysis of IL-33 and ST2 in mouse (B6RPE-07) and human (ARPE-19) RPE cells upon activation with TLR agonists. (D)
Immunofluorescence staining showing expression of IL-33 in adult murine retina. GCL= ganglion cell layer; IPL= inner plexiform layer;
INL= inner nuclear layer; OPL= outer plexiform layer; ONL= outer nuclear layer. Scale bar= 100 μm. (E) ST2 expression in choroidal mast
cells (arrows), choroidal fibroblasts (arrowheads), and RPE. (F) Immunofluorescence staining showing expression of IL-1 receptor accessory
protein (IL1RAP) in murine retina. Scale bar =100 μm. (G) Representative images of immunofluorescence staining showing expression of
IL-33, ST2, and IL1RAP in sections of human retina. Scale bar= 100 μm. Data are shown as mean± SEM. Data are representative of at least
three independent experiments with similar results. *p< 0.05. Statistical analysis was performed with Student’s t-test.
fibroblasts (vimentin+) (Figure 1E). Furthermore,
immunohistochemical analysis of murine retina
demonstrated that IL-1 receptor accessory protein
(IL1RAP) was expressed by cells in the retina and
RPE (Figure 1F). We next sought to determine whether
similar expression profiles were present in healthy
human ocular tissue. This revealed robust expression
of IL-33, ST2, and IL1RAP in the nerve fibre layer of
the inner retina and the RPE (Figure 1G). Furthermore,
IL-33 is known to be stored within red blood cells
[25], which may explain the strong IL-33 staining
within choroidal vessels (see supplementary material,
Figure S2).
Retinal endothelial cells are a direct target of IL-33
Although IL-33 is expressed in human choroidal vascu-
lar endothelium, IL-33 is down-regulated at the onset
of angiogenesis [26], suggesting a homeostatic role of
IL-33 regulation of tissue vasculature. To investigate fur-
ther, primary human retinal microvascular endothelial
cells (HRMECs) were cultured in the presence of IL-33.
First, we found that HRMECs responded to IL-33,
as evidenced by the increased production of down-
stream cytokine IL-6, as a marker of their activation,
when cultured with IL-33 (Figure 2A). Furthermore,
HRMECs expressed ST2 at high levels, compared with
monocytes (Figure 2B), and soluble ST2 was present in
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the supernatant of HRMECs (see supplementary mate-
rial, Figure S3A). More importantly, ST2 was almost
completely absent in other tissue-derived endothelial
cells, such as human cerebral microvascular endothelial
cells (HCMECs) (Figure 2B). As shown in Figure 2A,B,
HCMECs do not express IL-33 receptor and do not
respond to IL-33.
Next, we investigated the effect of IL-33 on the
migratory ability of HRMECs. Using a modified Boy-
den chamber, the chemotactic motility of HRMECs
was inhibited when incubated with recombinant
human IL-33, with the maximal effect at 100 ng/ml,
although proliferative responses remained unaltered
(Figure 2C,D and supplementary material, Figure S3B).
The inhibitory effect elicited by IL-33 treatment was
further demonstrated in a wound-healing assay, in
which there was a significant decrease in the migratory
ability of HRMECs (Figure 2E). We also assessed
the production of matrix metalloproteinase (MMP)-9,
and found that HRMECs produced significantly lower
levels of MMP9 in response to IL-33 stimulation
(Figure 2F). Furthermore, there was a small but sig-
nificant increase in the expression of tissue inhibitors
of metalloproteinases-1 (TIMP1) and -2 (TIMP2) upon
IL-33 treatment of HRMECs (Figure 2G). There was no
change in the expression of urokinase-type plasminogen
activator uPA (PLAU) or its receptor uPAR (PLAUR)
(Figure 2H), or of vascular endothelial growth factor
receptor (VEGFR)-1 (FLT1) or VEGFR2 (KDR) in
response to IL-33 (see supplementary material, Figure
S3C–E).
IL-33 regulates the function of human choroidal
fibroblasts
Alteration in choroidal architecture including vascular
changes and choroidal stromal thinning accompany-
ing fibrosis is associated with the RPE atrophy and
photoreceptor death as hallmarks of AMD [27]. As
choroidal fibroblasts express ST2, we wished to deter-
mine if IL-33 could attenuate responses as observed
with its anti-fibrotic and anti-hypertrophic effects
in the myocardium [28]. Experiments using human
choroidal fibroblasts demonstrated that cellular migra-
tion was significantly inhibited when incubated with
IL-33 (Figure 3A). Collagen gel contraction assays
have been widely used to evaluate the interaction of
fibroblasts with a collagenous matrix and their ability
to remodel this matrix [29–31]. Treatment of human
choroidal fibroblasts with IL-33 significantly inhibited
their ability to contract collagen gels by approximately
25% over the 12 h period examined, with no effect
on their proliferation (Figure 3B,C). A number of
factors including MMPs [32] are recognized to enhance
the migration and contraction of three-dimensional
collagen gels by fibroblasts. In response to IL-33, the
human choroidal fibroblasts expressed significantly
lower levels of both MMP2 and MMP9 (Figure 3D,E).
Furthermore, we found an increase in TIMP1 and
TIMP2 expression upon IL-33 stimulation of choroidal
fibroblasts (Figure 3F), while there was no change
in the expression of uPA (PLAU) or uPAR (PLAUR)
(Figure 3G).
Intravitreal administration of IL-33 attenuates CNV
To investigate a functional role of IL-33, we explored
its action in angiogenesis in the context of nAMD
using the murine model of laser-induced choroidal
neovascularization (CNV). Groups of mice received
an intravitreal injection of recombinant mouse IL-33
immediately following laser-induced CNV. Seven
days post-laser exposure, in vivo optical coherence
tomography (OCT) assessment and ex vivo isolectin-B4
(IB4) staining of RPE-choroidal flat mounts demon-
strated that CNV volume was significantly reduced
in eyes receiving IL-33 compared with the vehicle
control (Figure 4A,B). Furthermore, IB4 staining
revealed that two lower doses of IL-33 (200 pg/μl
and 1 ng/μl) were more effective at attenuating CNV
development, while the higher dose of 5 ng/μl IL-33
had no significant effect. This effect is similar to what
has been observed previously in a primate model of
immunotherapy with AMD [33]. Intravitreal IL-33 at
the dose of 200 pg/μl decreased choroidal neovascular
lesion (CNV) volume by up to 50% (Figure 4B,C).
This observation was manifest in reduced choroidal
neovascular lesions and disease severity (sub-retinal
fluid) in IL-33-treated eyes, as demonstrated in OCT
images (Figure 4A). Furthermore, the reduction in
clinical disease was accompanied by significantly
decreased c-kit+ cells, which demonstrated a poten-
tially reduced population of endothelial progenitor
cells in the lesions in IL-33-treated eyes compared
with control eyes (see supplementary material, Figure
S4A,B). Resident immune cells of the choroid include
macrophages and mast cells [34]. In addition to the
monocyte/macrophage cell infiltrate following laser
treatment, we found that tryptase-positive mast cells had
infiltrated CNV lesions (see supplementary material,
Figure S4C).
A recent report has suggested that endogenous
release of IL-33 triggers the recruitment of mono-
cytes contributing to photoreceptor loss [18]. To
examine this, RPE/choroidal tissue was collected
at 3 days post-laser exposure and intravitreal IL-33
injection, and immunostained for Iba1, a marker for
both microglia and monocytes. In the laser-induced
CNV model, macrophage numbers peak on day 3
following laser damage [35]. Our results showed that
Iba1+ cell accumulation was no different between
vehicle and IL-33-treated eyes. Furthermore, a 500-fold
increase to the therapeutic dose of IL-33 did not
influence Iba1+ cell accumulation in RPE/choroid
(see supplementary material, Figure S5A). In addi-
tion, monocyte recruitment was assessed via flow
cytometric analysis of the cell infiltrate from the
retinas of mice receiving either the low (200 pg/l)
or the high (100 ng/l) doses of IL-33. IL-33 treat-
ment did not lead to any significant increase of
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Figure 2. Retinal endothelial cells are a direct target of IL-33. (A) Production of IL-6 by HRMECs and HCMECs when treated with IL-33 for
varying amounts of time, measured by ELISA (n= 3 per group). (B) ST2L mRNA expression in HRMECs and HCMECs and human myeloid
cell line THP1 (n= 3 per group). (C) The Boyden chamber assay was performed and chemotactic activity was quantified by blind counting
of the migrating cells on the lower surface of the membrane in ten high-power microscope fields per chamber using a× 100 objective.
IL-33 significantly inhibited the migratory ability of HRMECs (scale bar= 50 μm) (n= 4 per group). (D) The MTT assay showed that IL-33
treatment had no effect on the proliferation of HRMECs (n= 3 per group). (E) IL-33 inhibited the migration of HRMECs in a wound-healing
assay (n= 5 per group). Scale bar= 100 μm. (F) Matrix metalloproteinase-9 (MMP9) mRNA expression in HRMECs in response to IL-33
(n= 3 per group). (G) Expression of tissue inhibitors of metalloproteinases-1 (TIMP1) and -2 (TIMP2) in HRMECs in response to IL-33 (n= 3
per group). (H) Urokinase-type plasminogen activator (uPA) and its receptor uPAR expression in HRMECs in response to IL-33 (n= 3 per
group). Data are shown as mean± SEM. Data are representative of at least two independent experiments with similar results. *p< 0.05.
Statistical analysis was performed with Student’s t-test.
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on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
IL-33 inhibits ocular angiogenesis 51
Figure 3. IL-33 regulates the function of human choroidal fibroblasts. IL-33 inhibited the ability of human choroidal fibroblasts to (A)
migrate in a wound-healing assay and (B) contract collagen gel (scale bar= 100 μm). (C) The MTT assay showed that IL-33 treatment
had no effect on their proliferation. (D) MMP2 and (E) MMP9 mRNA expression in choroidal fibroblasts upon treatment with IL-33. (F)
TIMP1 and TIMP2 expression in choroidal fibroblasts in response to IL-33 (n= 3 per group). (G) Expression of uPA and its receptor uPAR in
choroidal fibroblasts in response to IL-33 (n= 3 per group). Data are shown as mean± SEM. Data are representative of three independent
experiments with similar results. *p< 0.05. Statistical analysis was performed with Student’s t-test.
CD45+/CD11b+/Ly6C+ cells (see supplementary
material, Figure S5B).
To examine the safety and tolerability of recombi-
nant IL-33, groups of mice receiving varying doses of
IL-33 were clinically monitored using OCT at 3, 5, and
7 days post-injection. Histological and OCT analyses
of the retina at day 7 indicated that IL-33 administra-
tion did not alter retinal integrity and thickness, or result
in cell death (Figure 4D,E and supplementary material,
Figure S6A,B). Exogenous administration of recombi-
nant IL-33 had no effect on retinal pigment epithelial
(RPE) cell viability in vitro (see supplementary material,
Figure S6C).
ST2 is required for IL-33 anti-angiogenic properties
As exogenous IL-33 suppresses angiogenesis, we asked
if endogenous IL-33 is protective. To this end, we noted
that choroidal lesion volume measurements were more
pronounced in Il33−/− mice (Figure 4F). These results
open a plausible explanation that endogenous IL-33
expression may regulate but not significantly attenuate
CNV development in this model. To confirm that the
IL-33 effect was direct, we noted that IL-33 treatment
did not alter the severity of CNV development in St2−/−
mice (Figure 4G).
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 45–56
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Figure 4. Intravitreal administration of IL-33 attenuates CNV in an ST2-dependent manner. (A) Representative OCT images showing
choroidal neovascular lesions in control and IL-33-treated eyes. INL= inner nuclear layer; ONL= outer nuclear layer; RPE= retina pigment
epithelium. The white asterisk denotes the sub-retinal fluid. Scale bar= 200 μm. (B) Fluorescence IB4 staining of choroidal neovascular (CNV)
lesions in all treatment groups. Images are representative of CNV volume in each experimental group. Scale bar= 75 μm. (C) Quantitative
analysis of the volume of CNV lesions showed that the two lower doses of IL-33 significantly attenuated CNV development. IL-33 did not
affect the integrity and thickness of the retina, as shown in histological sections (D) and OCT analysis (E) of eyes that had only intravitreal
injection of IL-33. ONH= optic nerve head. Data are representative of two measurements per retina with four eyes per group. (F) Il33−/−
mice had more pronounced lesions but not to a statistically significant level. (G) IL-33 treatment did not affect the severity of CNV
development in St2−/−mice (n= 10 eyes per group). Data are shown as mean± SEM. Data are representative of at least three independent
experiments with similar results. *p< 0.05. Statistical analysis was performed with ANOVA with post-hoc t-test.
A truncated form of human IL-33 is biologically
active in mice
As mast cells are activated by IL-33 [15], murine bone
marrow-derived mast cells (BMMCs) were treated with
mouse and human IL-33, and IL-6 and IL-1β mRNA
levels were measured to compare their potency. We
found that BMMCs responded similarly to both forms
of IL-33 (Figure 5A), suggesting that human IL-33 is
bioactive in mice.
In vivo, administration of recombinant human IL-33
reduced angiogenesis, with the lower dose of 200 pg/μl
being the most effective (Figure 5B,C). Treatment with
human IL-33 had no effect on human RPE cell viabil-
ity in vitro (see supplementary material, Figure S6D).
Intravitreal administration did not induce cell death or
alter retinal integrity or thickness (Figure 5D,E and sup-
plementary material, Figure S6E,F).
Discussion
Our data demonstrate a protective role for IL-33 in
a murine model of injury-induced CNV. IL-33 is
expressed in the human retina and RPE, and IL-33 and
its cognate receptor are selectively expressed in primary
human retinal microvascular endothelial cells. Local
administration of recombinant IL-33 protected against
the development of CNV, supporting its immunomod-
ulatory therapeutic potential for nAMD [6,33,36].
IL-33 suppression of CNV does not support a primary
VEGF dependency because VEGFR levels remained
unchanged, but instead supports a direct inhibition of
ST2-positive fibroblasts and endothelial cells.
Current anti-VEGF therapies arguably do not address
major aspects of the underlying pathophysiology, such
as circumventing inflammation and wound healing
leading to angiogenesis. Furthermore, VEGF’s role
as a neuronal survival factor cannot be overlooked,
underscored by the observation that in patients receiv-
ing long-term anti-VEGF therapy the neural retina
can begin to degenerate [2]. These data and others’
question the current development of therapeutic tar-
gets redressing either complement dysregulation or
inhibiting the assumed negative impact of chronic
low-grade inflammation such as inflammasome acti-
vation [37]. The identification of an anti-angiogenic
role of IL-33 in CNV extends current understanding
of the functional diversity of members of the IL-1
family in angiogenesis. For example, IL-1 receptor
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Figure 5. A truncated form of human IL-33 is biologically active in mice. (A) We used a truncated form of human IL-33, which is bioactive
in mice, as shown by IL-6 and IL-1β mRNA levels produced by bone marrow-derived mast cells (BMMCs) upon treatment with mouse and
human IL-33. (B) Representative images of OCT showing choroidal neovascular lesions in control and human IL-33-treated eyes. INL= inner
nuclear layer; ONL= outer nuclear layer; RPE= retina pigment epithelium. The white asterisk denotes the sub-retinal fluid. Scale bar= 200
μm. (C) Immunofluorescence IB4 staining and quantitative analysis of choroidal neovascular lesions in all treatment groups with normal
saline or human IL-33. Images are representative of CNV volume in each experimental group. Scale bar= 75 μm. (D) Representative images
of histology in control and eyes treated only with intravitreal injections (n= 4 eyes per group). (E) The truncated form of human IL-33 did
not affect the thickness of the retina, as measured by OCT in eyes that had intravitreal injection of IL-33. ONH= optic nerve head. Data
are representative of two measurements per retina with four eyes per group. Data are shown as mean± SEM and are representative of at
least two independent experiments with similar results. *p< 0.05. Statistical analysis was performed with ANOVA with post-hoc t-test.
antagonist treatment significantly inhibits CNV, as
there is a direct effect of IL-1β on choroidal endothe-
lial cell proliferation [38]. On the other hand, IL-18
production following inflammasome activation sup-
presses CNV and down-regulates VEGFR signalling
[36]. IL-33 treatments directly inhibit the migration
of retinal endothelial cells and choroidal fibroblasts
without down-regulation of VEGFR and appear to be
potent in reducing angiogenic responses. Conceivably,
IL-33 may synergize with IL-18 and further amplify
an anti-angiogenic response in both early and late
phases of the disease. IL-33 is bioactive without requir-
ing the NLRP3 inflammasome and caspase cleavage
[8]. Inflammatory cues strongly induce expression of
endogenous IL-33 [39]. Indeed, whether IL-33 is also
liberated following intravitreal IL-4 administration
directing a macrophage-mediated suppression of CNV
warrants further investigation [40].
Supporting the diverse constitutive tissue expres-
sion of IL-33 [7,41], the current data show IL-33
and ST2 expression in human and murine RPE. Many
RPE-derived molecules are central to regulating and
maintaining local immune privilege in the eye [42]. To
support a regulatory behaviour, IL-33 is constitutively
expressed by cells in the inner nuclear layer (INL) of
the retina, displaying eye-specific homeostatic expres-
sion similar to others’ data [18]. Although IL-33 is
released from Müller cells in vitro and in vivo after
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phototoxic stress [18], and the effect is detrimental,
we have shown TLR-induced up-regulation of IL-33
in RPE cells without cell death. This likely repre-
sents an attempt to maintain homeostasis and tissue
health. In support of our observation, Kakkar et al have
reported that IL-33 is localized simultaneously to both
nuclear euchromatin and membrane-bound cytoplasmic
vesicles, and have demonstrated that mechanical strain
induced IL-33 secretion in the absence of cellular necro-
sis in murine fibroblasts [10]. We speculate a simi-
lar dynamic inter-organelle trafficking of IL-33 in RPE
under stress, which induces increased membrane-bound
cytoplasmic vesicles and subsequent IL-33 release with-
out cell death.
Endogenous intracellular IL-33 does not alter the
development of angiogenesis in the laser-CNV model.
The lack of effect with loss of endogenous IL-33 can be
explained by the low level of its basal expression in nor-
mal tissue. We speculate that IL-33 acts as an in-built
brake and that under stress conditions, as shown in vitro
(Figure 1), IL-33 is up-regulated, regulating angiogene-
sis. To support this notion, exogenous recombinant IL-33
suppresses CNV. Further, we found that the two lower
doses of murine IL-33 were more efficient at reducing
CNV development. We speculate that higher doses of
IL-33 up-regulate ST2 expression, neutralizing IL-33
activity. Such a possibility is consistent with our in vitro
data demonstrating IL-33-induced enhancement of the
IL-33/ST2 axis in the RPE. Furthermore, we found no
adverse effect of exogenous application of IL-33, as
reported previously [18]. Injection of 500-fold higher
than the therapeutic dose of recombinant IL-33 did not
induce cell death or increasedmonocyte recruitment (see
supplementary material, Figure S5).
IL-33 exhibits unique features and represents a
guardian of barriers and a local alarmin [43]. In an
intact barrier, cellular contacts provide the signals to
produce full-length IL-33 ‘constitutively’ but neither
process nor release it. In these barrier cells, full-length
IL-33 resides in the nucleus, where it controls gene
expression and is possibly involved in maintaining
the cells’ resting state [43]. During injury, some of
the barrier cells are destroyed and full-length IL-33
is liberated. Depending on the location of the barrier
and the cause of perturbation, the bioactivity and effect
of extracellular IL-33 will be different. Although trig-
gers differ, the basic principles of alarming resident
sentinel cells via IL-33 may yet apply. Extracellular
IL-33 coordinates immune defence and repair mech-
anisms, and elucidating the local effects of IL-33
enables a rationally based approach to developing
pharmacological intervention strategies to target the
IL-33/ST2 axis. IL-33 is expressed in multiple endothe-
lial cells [26,28], and exogenous administration of
IL-33 induces the expression of adhesion molecules
and inflammatory cytokines [44]. The presence of
mast cells within CNV lesions infers the possibil-
ity of additional sources of IL-33 and the ability to
rapidly process IL-33 delivering enhanced biological
activity, augmenting local immune responses [43].
On the other hand, IL-33 has anti-hypertrophic and
anti-fibrotic effects [45]. Despite data indicating that
IL-33 promotes angiogenesis [46], we believe that this
is tissue context-dependent, in that endothelial IL-33
receptor expression has tissue specificity. Human retinal
endothelial cells express ST2 at high levels, compared
with monocytes, and ST2 is almost completely absent
in human brain endothelial cells (Figure 2B) which do
not respond to IL-33 treatment. Cytokine pleiotropism
is supported because IL-33 exacerbates autoimmune
collagen-induced arthritis via mast cell degranulation
[20], but IL-33 elicits high levels of IL-5 and IL-13
[45], driving M2 macrophages and protecting against
EAU [17] and atherosclerosis [45]. IL-33 prevents cog-
nitive decline in mouse models of Alzheimer’s disease
[47] and inhibits atherosclerosis [45], and here IL-33
also directly inhibited choroidal fibroblast activity,
implicating a potentially wider role clinically. These
actions add to the increasing evidence and support
for immunotherapeutic mediated adjuncts to aid the
current treatment paradigm for patients suffering from
nAMD [48].
Acknowledgements
Researchwas funded through the National Eye Research
Centre, UK (RJ6056). ADD and ST were supported in
part through the National Institute for Health Research,
UK. Additional support was received from the National
Institute for Health Research (NIHR) Biomedical
Research Centre based at Moorfields Eye Hospital
NHS Foundation Trust and University College Lon-
don Institute of Ophthalmology. SD is supported by
grants from Science Foundation Ireland (SFI), The
Health Research Board of Ireland (HRB), and the
Bright Focus Foundation. MC was supported by grants
from Science Foundation Ireland (SFI), The Health
Research Board of Ireland (HRB) and the Bright
Focus Foundation. The views expressed are those of
the authors and not necessarily those of the National
Health Service, the NIHR or the Department of Health.
We would like to thank Costanza Emanueli (School
of Clinical Sciences, Bristol Heart Institute, Univer-
sity of Bristol, Bristol, UK) for providing the ST2
knock-out (St2−/−) C57BL/6 mice. Additionally, we
would like to thank Professor Seamus Martin and
Dr Graeme Sullivan for providing human recombi-
nant IL-33. We would also like to acknowledge the
assistance of the Flow Cytometry Facility and the
Wolfson Bioimaging Facility at the University of
Bristol.
Author contribution statement
ADD conceived the project and supervised all research.
ST, DAC, JL, JW, PJG, EO, andMC performed research.
ST, DAC, SLD, and MC analysed data. ST, DAC, SLD,
MC, and ADD wrote the manuscript.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 45–56
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
IL-33 inhibits ocular angiogenesis 55
References
1. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related
macular degeneration through the year 2050: the potential impact of
new treatments. Arch Ophthalmol 2009; 127: 533–540.
2. Xu L, Mrejen S, Jung JJ, et al. Geographic atrophy in patients
receiving anti-vascular endothelial growth factor for neovascular
age-related macular degeneration. Retina 2015; 35: 176–186.
3. Nussenblatt RB, Lee RW, Chew E, et al. Immune responses in
age-related macular degeneration and a possible long-term therapeu-
tic strategy for prevention. Am J Ophthalmol 2014; 158: 5–11.e12.
4. Lamkanfi M. Emerging inflammasome effector mechanisms. Nature
Rev Immunol 2011; 11: 213–220.
5. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina.
Prog Retin Eye Res 2009; 28: 348–368.
6. Doyle SL, Ozaki E, Brennan K, et al. IL-18 attenuates experi-
mental choroidal neovascularization as a potential therapy for wet
age-related macular degeneration. Sci Transl Med 2014; 6: 230ra244.
7. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like
cytokine that signals via the IL-1 receptor-related protein ST2 and
induces T helper type 2-associated cytokines. Immunity 2005; 23:
479–490.
8. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated
after maturation by caspase-1. Proc Natl Acad Sci U S A 2009; 106:
9021–9026.
9. Lefrancais E, Roga S, Gautier V, et al. IL-33 is processed into mature
bioactive forms by neutrophil elastase and cathepsin G. Proc Natl
Acad Sci U S A 2012; 109: 1673–1678.
10. Kakkar R, Hei H, Dobner S, et al. Interleukin 33 as a mechanically
responsive cytokine secreted by living cells. J Biol Chem 2012; 287:
6941–6948.
11. LamkanfiM, Dixit VM. IL-33 raises alarm. Immunity 2009; 31: 5–7.
12. Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor acces-
sory protein and ST2 comprise the IL-33 receptor complex. J
Immunol 2007; 179: 2551–2555.
13. Yanagisawa K, Tsukamoto T, Takagi T, et al. Murine ST2 gene is
a member of the primary response gene family induced by growth
factors. FEBS Lett 1992; 302: 51–53.
14. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable
cell surface molecule on type 2 but not type 1 helper T cells. J Exp
Med 1998; 187: 787–794.
15. Allakhverdi Z, Smith DE, Comeau MR, et al. Cutting edge: the ST2
ligand IL-33 potently activates and drives maturation of human mast
cells. J Immunol 2007; 179: 2051–2054.
16. Leung BP, Xu D, Culshaw S, et al. A novel therapy of murine
collagen-induced arthritis with soluble T1/ST2. J Immunol 2004;
173: 145–150.
17. Barbour M, Allan D, Xu H, et al. IL-33 attenuates the develop-
ment of experimental autoimmune uveitis. Eur J Immunol 2014; 44:
3320–3329.
18. Xi H, Katschke KJ Jr, Li Y, et al. IL-33 amplifies an innate immune
response in the degenerating retina. J Exp Med 2016; 213: 189–207.
19. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of
IL-33: the new kid in the IL-1 family. Nature Rev Immunol 2010; 10:
103–110.
20. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced
arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008; 105:
10913–10918.
21. Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of
innate rather than acquired immunity.Proc Natl Acad Sci U S A 2010;
107: 18581–18586.
22. Luthi AU, Cullen SP, McNeela EA, et al. Suppression of
interleukin-33 bioactivity through proteolysis by apoptotic caspases.
Immunity 2009; 31: 84–98.
23. Chen M, Muckersie E, Robertson M, et al. Characterization of a
spontaneous mouse retinal pigment epithelial cell line B6-RPE07.
Invest Ophthalmol Vis Sci 2008; 49: 3699–3706.
24. Dunn KC, Aotaki-Keen AE, Putkey FR, et al. ARPE-19, a human
retinal pigment epithelial cell line with differentiated properties. Exp
Eye Res 1996; 62: 155–169.
25. Wei J, Zhao J, Schrott V, et al. Red blood cells store and release
interleukin-33. J Investig Med 2015; 63: 806–810.
26. Kuchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33
is generally expressed in resting endothelium but rapidly lost upon
angiogenic or proinflammatory activation. Am J Pathol 2008; 173:
1229–1242.
27. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest 2007;
117: 576–586.
28. Chen WY, Hong J, Gannon J, et al. Myocardial pressure overload
induces systemic inflammation through endothelial cell IL-33. Proc
Natl Acad Sci U S A 2015; 112: 7249–7254.
29. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure
by contraction of collagen lattices by human fibroblasts of different
proliferative potential in vitro. Proc Natl Acad Sci U S A 1979; 76:
1274–1278.
30. Guidry C, Grinnell F. Contraction of hydrated collagen gels by
fibroblasts: evidence for two mechanisms by which collagen fibrils
are stabilized. Coll Relat Res 1987; 6: 515–529.
31. Carver W, Molano I, Reaves TA, et al. Role of the alpha 1 beta 1
integrin complex in collagen gel contraction in vitro by fibroblasts. J
Cell Physiol 1995; 165: 425–437.
32. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metallopro-
teinase inhibition modulates fibroblast-mediated matrix contraction
and collagen production in vitro. Invest Ophthalmol Vis Sci 2003; 44:
1104–1110.
33. Doyle SL, Lopez FJ, Celkova L, et al. IL-18 immunotherapy for
neovascular AMD: tolerability and efficacy in nonhuman primates.
Invest Ophthalmol Vis Sci 2015; 56: 5424–5430.
34. McMenamin PG. The distribution of immune cells in the uveal tract
of the normal eye. Eye (Lond) 1997; 11: 183–193.
35. Liu J, Copland DA, Horie S, et al. Myeloid cells expressing VEGF
and arginase-1 following uptake of damaged retinal pigment epithe-
lium suggests potential mechanism that drives the onset of choroidal
angiogenesis in mice. PLoS One 2013; 8: e72935.
36. Campbell M, Doyle S, Humphries P. IL-18: a new player in
immunotherapy for age-related macular degeneration? Expert Rev
Clin Immunol 2014; 10: 1273–1275.
37. Doyle SL, Campbell M, Ozaki E, et al. NLRP3 has a protective
role in age-related macular degeneration through the induc-
tion of IL-18 by drusen components. Nature Med 2012; 18:
791–798.
38. Lavalette S, Raoul W, Houssier M, et al. Interleukin-1β inhi-
bition prevents choroidal neovascularization and does not
exacerbate photoreceptor degeneration. Am J Pathol 2011; 178:
2416–2423.
39. Pichery M, Mirey E, Mercier P, et al. Endogenous IL-33 is highly
expressed in mouse epithelial barrier tissues, lymphoid organs,
brain, embryos, and inflamed tissues: in situ analysis using a
novel Il-33-LacZ gene trap reporter strain. J Immunol 2012; 188:
3488–3495.
40. Wu WK, Georgiadis A, Copland DA, et al. IL-4 regulates specific
Arg-1(+) macrophage sFlt-1-mediated inhibition of angiogenesis.
Am J Pathol 2015; 185: 2324–2335.
41. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine
ligand for ST2 receptor, is a chromatin-associated nuclear factor in
vivo. Proc Natl Acad Sci U S A 2007; 104: 282–287.
42. Forrester JV, Xu H, Lambe T, et al. Immune privilege or privileged
immunity?Mucosal Immunol 2008; 1: 372–381.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 45–56
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
56 S Theodoropoulou et al
43. Martin NT, Martin MU. Interleukin 33 is a guardian of barriers and
a local alarmin. Nature Immunol 2016; 17: 122–131.
44. Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces
expression of adhesion molecules and inflammatory activation in
human endothelial cells and in human atherosclerotic plaques. Arte-
rioscler Thromb Vasc Biol 2011; 31: 2080–2089.
45. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development
of atherosclerosis. J Exp Med 2008; 205: 339–346.
46. Choi YS, Choi HJ,Min JK, et al. Interleukin-33 induces angiogenesis
and vascular permeability through ST2/TRAF6-mediated endothelial
nitric oxide production. Blood 2009; 114: 3117–3126.
47. Fu AK, Hung KW, Yuen MY, et al. IL-33 ameliorates Alzheimer’s
disease-like pathology and cognitive decline. Proc Natl Acad Sci U S
A 2016; 113: E2705–E2713.
48. Dick AD. Enhancing inflammation as an adjuvant to neovascular
AMD therapy. Invest Ophthalmol Vis Sci 2015; 56: 5431.
SUPPLEMENTARY MATERIAL ONLINE
Supplementary materials and methods
Supplementary figure legends
Figure S1. Expression pattern and localization of IL-33 in developing retina
Figure S2. Expression of IL-33 in adult human ocular tissue
Figure S3. Effect of IL-33 on retinal endothelial cells
Figure S4. Reduced population of endothelial progenitor cells in IL-33 eyes with CNV
Figure S5. Recombinant IL-33 does not increase monocyte recruitment in retina
Figure S6. Safety and tolerability of IL-33
50 Years ago in the Journal of Pathology…
Chemodectoma of the pineal region, with observa?ons on the pineal body and chemo-
receptor ?ssue 
W. Thomas Smith, Brodie Hughes and R. Ermocilla 
Tumours in young chickens bred for rapid body growth (broiler chickens): A study of 351 
cases  
J. G. Campbell and E. C. Appleby 
The incidence of tumours in young chickens  
L. A. Hemsley 
To view these ar?cles, and more, please visit:
www.thejournalofpathology.com
Click ‘ALL ISSUES (1892 - 2016)’, to read articles going right back to Volume 1, 
Issue 1. 
The Journal of Pathology 
Understanding Disease 
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 241: 45–56
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
